Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 731-740

  Galaup, Ariane ^a   Opolon, Paule ^a   Bouquet, Céline ^a   Li, Hong ^a   Opolon, David ^a   Bissery, Marie Christine ^b   Tursz, Thomas ^c   Perricaudet, Michel ^a   Griscelli, Frank ^a  

^a CNRS   (France)

^b SANOFI   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adenovirus; Angiostatin; Anti angiogenesis; Docetaxel; Prostate tumor

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; DOCETAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER REGRESSION; CANCER SIZE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0038392764     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00121-7     Document Type: Article

References (30)

1. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
2. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82: 4-6.
3. Mauceri, H. J., et al. (1998). Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-290.
4. Folkman, J., and Camphausen, K. (2001). What does radiotherapy do to endothelial cells. Science 293: 227-228.
5. Kerbel, R. S. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515.
6. Vacca, A., et al. (2000). Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. 11: 103-118.
7. Belloti, D., et al. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2: 1843-1849.
8. O'Leary, J. J., Shapiro, R. L., Ren, C. J., Chuang, N., Cohen, H. W., and Potmesil, M. (1999). Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 5: 181-187.
9. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., and Zwi, L. J. (1991). Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 27: 482-487.
10. Schirner, M., Hoffmann, J., Menrad, A., and Schneider, M. R. (1998). Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin. Cancer Res. 4: 1331-1336.
11. Hirata, S., Matsubara, T., Saura, R., Tateidhi, H., and Hirohata, K. (1989). Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32: 1065-1073.
12. Browder, T., et al. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60: 1878-1886.
13. O'Reilly, M. S., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
14. Parangi, S., et al. (1996). Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93: 2002-2007.
15. Gately, S., et al. (1996). Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56: 4887-4890.
16. O'Mahony, C. A., Seidel, A., Albo, D., Chang, H., Tuszynski, G. P., and Berger, D. H. (1998). Angiostatin generation by human pancreatic cancer. J. Surg. Res. 77: 55-58.
17. Westphal, J. R., et al. (2000). Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int. J. Cancer 86: 760-767.
18. Griscelli, F., et al. (1998). Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA 95: 6367-6372.
19. Tanaka, T., Cao, Y., Folkman, J., and Fine, H. A. (1998). Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58: 3362-3369.
20. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
21. Griscelli, F., et al. (2000). Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA 97: 6698-6703.
22. Small, E. J. (2001). Docetaxel in prostate cancer. Anti-cancer Drugs 12: 17-20.
23. Stein, C. A. (1999). Mechanisms of action of taxanes in prostate cancer. Semin. Oncol. 26: 3-7.
24. Vacca, A., et al. (2002). Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. 11: 103-118.
25. Nielen, L. L., Lipari, P., Dell, J., Gurnani, M., and Hajian, G. (1998). Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4: 835-846.
26. Yu, D. C., et al. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61: 517-525.
27. Leopold, P. L., et al. (2000). Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum. Gene Ther. 11: 151-165.
28. Filleur, S., et al. (2001). In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 15: 1373-1382.
29. Stratford-Perrricaudet, L. D., Levrero, M., Chasse, J. F., Perricaudet, M., and Briand, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1: 241-256.
30. Chou, T. C., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22: 27-55.